Reproductive BioMedicine Online
Volume 20, Issue 4 , Pages 504-509, April 2010

Double measurements of serum HCG concentration and its ratio may predict IVF outcome

Center of Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, 49 North Garden Rd, Beijing 100191, China

Received 27 April 2009; received in revised form 28 May 2009; accepted 3 December 2009. published online 08 March 2010.

Declaration: The authors report no financial or commercial conflicts of interest.

Abstract 

Serum human chorionic gonadotrophin (HCG) concentration is nearly always used to predict pregnancy but there is little data on the clinical utility of the ratio of HCG21/HCG14 combined with double measurement of serum HCG. A total of 1762 cycles were retrospectively analysed for serum HCG concentration and ratio of HCG21/HCG14 on days 14 and 21 after embryo transfer to determine whether the ratio combined with concentration is the optimal predictor of pregnancy. The medians of HCG concentration on days 14 and 21 combined with the ratio of HCG21/HCG14 were calculated for non-viable, viable and heterotopic pregnancies. HCG concentrations of 290IU/l on day 14 and 2970IU/l on day 21 were regarded as the cut-off values to predict viable pregnancy, and values of 630 and 12,000IU/l, respectively, were regarded as the cut-off values to predict multiple pregnancy. The ratio of HCG21/HCG14 in the viable pregnancy group was significantly higher than that in the non-viable pregnancy group (15.86 versus 5.27, P<0.0001). For heterotopic pregnancy, the ratio of HCG21/HCG14 was 11.93. It was concluded that HCG concentration on days 14 and 21 combined with the ratio of HCG21/HCG14 provides a useful predictor of pregnancy outcome. A ratio >15 may predict viable pregnancy.

Keywords: human chorionic gonadotrophin, IVF, outcome, pregnancy, ratio

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Hongbin Chi received her MD in 2006 from the Shanghai Jiao Tong University in China. She is an Associate Professor and works at the Medical Center for Human Reproduction, Department of Obstetrics and Gynaecology, Peking University Third Hospital, Beijing. She has a particular interest in reproductive hormone testing for predicting the outcomes of assisted reproductive technology. She specializes in diagnoses and management of infertility and reproductive endocrine diseases.

PII: S1472-6483(10)00006-4

doi:10.1016/j.rbmo.2010.01.005

Reproductive BioMedicine Online
Volume 20, Issue 4 , Pages 504-509, April 2010